Mr.PotatoHead does not own CHTP shares but he can use the drug to help him.
JImmy Durante bleeds Notre Dame gold-thats not my business! GLTA
Very difficult to accomplish but always that slim possibility-An NDA resubmittal without new trial needed would be a win.IF Titan somehow has dusted off old data that wasnt present on their NDA,maybe there is something that catches the positive attention of FDA.
There is also the REMS that still needs to be negotiated and the Human Factors Study that will still need to be done.Disappointing that all this time has passed and at the least' Titan/Braeburn could have started and almost finished this study by now...FDA will not approve without this specific study done.
Shorthall needs to 'show me the money' and then the shorts will slowly go away-
Cant blame shorts for taking adavantage of an opportunity that Alan has allowed to occur-
ONe HUGE upfront cash deal would go a long way into Unilife getting a good reputation and shutting up the haters-meanwhile,longs patiently wait for that one MEGA deal..
Any upcoming deals with large upfront cash attached to them of course would resolve this money issue Unilife is facing..f these deals are really production/supply agreements for commercial sales,then Unilife needs to expand pronto! IF they dont commence expansion then something is fishy..
If all current and future deals are legit,and hundreds of millions of syringes need to be produced next year or two the current facility can not accomplish this-THey need lots of cash and expansion capabilities-tapping the ATM is not enough to cover day to day normal operations- R&D,and production line expansion-I am just guessing but i would think they need 50+million...
These announcements are nice, but they are fluff until big money is attached to them which many of these type deals are lacking..They are future potential money deals, however Unilife needs alot of cash now to operate in order to avoid dilution. When a company doesnt announce amount of deal,that usually means it is not currently financially material to warrant disclosing.
THey need to announce multi deals with 10 20 0 50 million each attached to them-
Unilife has bills to pay and if they want to manufacture product if the demand is real,well they need to expand ASAP..
Why would you predict that? you are so wrong Sir.
Big pharma could talk to company if Aldo can get New Chemical Status from FDA, then patent protection for Aldo is appealing to the big boys..
Not always easy to continue to hold a stock through a postive event..
I sold at 4.03 from 2.10 average buy in- thinking stock will take the typical post-catalyst drop-
This stock currently doing the opposite -- up up up''
WaS the Doxo dosage used in this trial a typical patient dosage or was it less than the norm usually given to these patient population? That 'might' explain the low or non existent response rate in doxo arm
Also,for other type cancers where doxorubicin is used,drug is combined as a cocktail and not used by itself so Aldo still has hurdles to overcome in clinical trials-However,these current results at the least is promising for soft tissue sarcoma.The 2014 overall survival data will be huge IF favorable to Aldo.
You bought today? after the results announced?
yes tmrrw prob declines a little however the 10.00 potential down the road has not changed-
Though a secondary endpoint,IF OS data in 2014 turns out good then woooo woooo money train..
BIG PHARMA will be watching very closely.
OH Brother! lol good for him
I sold at 4.03 pre-market-Old saying,if you dont take your profits,somebody else will!
Stock still has 10.00 potential down the road.
I will take the 1% you left out and stick it to you where the sun dont shine kiddo! lol
actually,there is always the chance of no trials but odds are slim,not 99% favorable..
THe key is to make money GAMBLING/INVESTING in stocks whether a drug is worthless or a billion dollars...
LIAR REMS has not been taken care of yet- There have been NO discussions with FDA on REMS since CRL given.
As for a buyout,that is a possibility IF the brain cancer trial is a success-
thats a potential 500mil-billion dollar yearly drug.
Of course they need more money-2 clinical trials coming up-
however,BIG PHARMA may approach with a partnership and upfront cash.